OCUGEN, INC. Cash
OCUGEN, INC. (OCGN) had Cash of $31.86 million as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-05-08
- 2026-03-31: Cash $31.86M.
- 2025-12-31: Cash $18.57M.
- 2025-09-30: Cash $32.56M.
- 2025-06-30: Cash $27.01M.
| Period end | Cash |
|---|---|
| 2026-03-31 | $31.86M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $18.57M 10-Q · filed 2026-05-08 |
| 2025-09-30 | $32.56M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $27.01M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $37.80M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $58.51M 10-K · filed 2026-03-04 |
| 2024-09-30 | $38.70M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $15.70M 10-Q · filed 2025-08-04 |
| 2024-03-31 | $26.38M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $39.46M 10-K · filed 2025-03-05 |
| 2023-09-30 | $53.48M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |